Technology area: Biotechnology & Pharmaceuticals
50 pending office actions • 30 art units • 48 examiners • 0 of 50 (0%) have an AI response strategy ready • 64 patents granted in the last 365 days
DANA-FARBER CANCER INSTITUTE, INC. operates within the Biotechnology & Pharmaceuticals technology area, where it currently has 2 pending office actions. These 2 pending office actions are distributed among 2 distinct examiners, indicating that each case is being handled by a different individual. This distribution requires the company to manage multiple examiner perspectives within its current prosecution strategy.
The portfolio is spread across 2 distinct art units, suggesting that the company's innovations touch upon different technical sub-specialties within the biotechnology sector. TICHY, JENNIFER M.H. is identified as the busiest examiner for the portfolio, currently overseeing 1 busiest examiner pending office action. This 1 busiest examiner pending office action represents half of the total pending workload for the company.
For practitioners, the presence of 2 distinct examiners and 2 distinct art units for only two pending actions indicates a diverse prosecution environment. Each case requires a unique approach tailored to the specific art unit and examiner involved. Consistency across the portfolio is important, as the distinct examiners may have different interpretations of the technical disclosures in the Biotechnology & Pharmaceuticals area.
Based on the USPTO statutory response window for each pending office action. 26 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 26 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (2%) |
| §101 + other | 4 (8%) |
| §103 only | 6 (12%) |
| §102 only | 2 (4%) |
| §112 only | 11 (22%) |
| Double-patenting only | 1 (2%) |
| Double-patenting + other | 5 (10%) |
| Multi-statute (no §101) | 18 (36%) |
| No statute on record | 2 (4%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VASSELL, MEREDITH ABBOTT | 2 | 29.9% | +45.8% |
| VIVLEMORE, TRACY ANN | 2 | 73.0% | +6.4% |
| MYERS, CARLA J | 1 | 49.5% | +46.0% |
| PAK, YONG D | 1 | 74.7% | +14.2% |
| WILDER, CYNTHIA B | 1 | 70.8% | +27.0% |
| OLSON, ALEXANDRA NADINE | 1 | 100.0% | +0.0% |
| OUSPENSKI, ILIA I | 1 | 77.3% | +20.6% |
| HAVLIN, ROBERT H | 1 | 51.3% | +28.3% |
| NEAGU, IRINA | 1 | 46.7% | +57.2% |
| YOO, SUN JAE | 1 | 71.2% | +0.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18650592 | BIOLOGICALLY SELECTED NUCLEIC ACID ARTIFICIAL MINI-PROTEOME LIBRARIES | OLSON, ALEXANDRA NADINE | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17732926 | BLOOD-BASED BIOMARKERS AND USE THEREOF FOR TREATING CANCER | MCCOLLUM, ANDREA K | 309d overdue |
| 17801709 | POTENT AND SELECTIVE DEGRADERS OF ALK | HEITMEIER, KENDALL NICOLE | 182d overdue |
| 17402018 | GENETIC ABNORMALITIES IN PLASMA CELL DYSCRASIAS | GOLDBERG, JEANINE ANNE | 131d overdue |
| 17414480 | METHODS FOR IDENTIFYING NEOANTIGENS | FONSECA LOPEZ, FRANCINI ALVARENGA | 58d overdue |
| 17265139 | HISTONE DEMETHYLASE 5 INHIBITORS AND USES THEREOF | PECKHAM, RICHARD GRANT | 42d overdue |
| 17241935 | DRUG DELIVERY COMPOSITIONS AND USES THEREOF | MERTZ, PREMA MARIA | 29d overdue |
| 18026746 | METHODS OF TREATING AN INDIVIDUAL THAT HAS FAILED AN ANTI-PD-1/ANTI-PD-L1 THERAPY | BENAVIDES, JENNIFER ANN | 18d overdue |
| 18031257 | GERMLINE BIOMARKERS OF CLINICAL RESPONSE AND BENEFIT TO IMMUNE CHECKPOINT INHIBITOR THERAPY | HINES, JANA A | 15d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19098448 | IDENTIFICATION OF SOMATIC OR GERMLINE ORIGIN FOR CELL-FREE DNA | VASSELL, MEREDITH ABBOTT | 16d |
| 19440954 | IDENTIFICATION OF SOMATIC OR GERMLINE ORIGIN FOR CELL-FREE DNA | VASSELL, MEREDITH ABBOTT | — |
| 19397515 | UNIVERSAL EARLY CANCER DIAGNOSTICS | MYERS, CARLA J | — |
| 18960980 | SYSTEMS, COMPOSITIONS AND METHODS FOR IDENTIFYING E3 LIGASE SUBSTRATES BY UBIQUITIN BIOTINYLATION | PAK, YONG D | — |
| 18710722 | ENZYME-FREE ISOTHERMAL EXPONENTIAL AMPLIFICATION | WILDER, CYNTHIA B | — |
| 18699108 | ENGINEERED CYTOKINE RECEPTORS FOR TUNABLE ADOPTIVE CELL THERAPY | OUSPENSKI, ILIA I | — |
| 18580725 | INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) | HAVLIN, ROBERT H | — |
| 18576068 | DEGRADERS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 AND USES THEREOF | NEAGU, IRINA | — |
| Art Unit | Apps |
|---|---|
| 1682 | 3 |
| 1628 | 3 |
| 1624 | 3 |
| 1627 | 3 |
| 1643 | 3 |
| 1687 | 2 |
| 1652 | 2 |
| 1644 | 2 |
| 1629 | 2 |
| 1621 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19440954 | IDENTIFICATION OF SOMATIC OR GERMLINE ORIGIN FOR CELL-FREE DNA | VASSELL, MEREDITH ABBOTT | 1687 | §101§103DP | Final Rejection | — | Pending | Jan 06, 2026 |
| 19397515 | UNIVERSAL EARLY CANCER DIAGNOSTICS | MYERS, CARLA J | 1682 | §101§102§103§112DP | Final Rejection | — | Pending | Nov 21, 2025 |
| 19098448 | IDENTIFICATION OF SOMATIC OR GERMLINE ORIGIN FOR CELL-FREE DNA | VASSELL, MEREDITH ABBOTT | 1687 | §101DP | Non-Final OA | 16d | Pending | Apr 02, 2025 |
| 18960980 | SYSTEMS, COMPOSITIONS AND METHODS FOR IDENTIFYING E3 LIGASE SUBSTRATES BY UBIQUITIN BIOTINYLATION | PAK, YONG D | 1652 | §112 | Non-Final OA | — | Pending | Nov 26, 2024 |
| 18710722 | ENZYME-FREE ISOTHERMAL EXPONENTIAL AMPLIFICATION | WILDER, CYNTHIA B | 1681 | §103§112 | Non-Final OA | — | Pending | May 16, 2024 |
| 18650592 | BIOLOGICALLY SELECTED NUCLEIC ACID ARTIFICIAL MINI-PROTEOME LIBRARIES | OLSON, ALEXANDRA NADINE | 1684 | §103§112DP | Non-Final OA | — | Pending | Apr 30, 2024 |
| 18699108 | ENGINEERED CYTOKINE RECEPTORS FOR TUNABLE ADOPTIVE CELL THERAPY | OUSPENSKI, ILIA I | 1644 | §102§112DP | Non-Final OA | — | Pending | Apr 05, 2024 |
| 18580725 | INHIBITORS TARGETING UBIQUITIN SPECIFIC PROTEASE 7 (USP7) | HAVLIN, ROBERT H | 1626 | §102§103§112Other | Non-Final OA | — | Pending | Jan 19, 2024 |
| 18576068 | DEGRADERS OF WILD-TYPE AND MUTANT FORMS OF LRRK2 AND USES THEREOF | NEAGU, IRINA | 1629 | §103§112 | Non-Final OA | — | Pending | Jan 02, 2024 |
| 18399092 | 6-PHENYL-4,5-DIHYDROPYRIDAZIN-3(2H)-ONE DERIVATIVES AS PDE3A AND PDE3B INHIBITORS FOR TREATING CANCER | YOO, SUN JAE | 1621 | §112 | Non-Final OA | 26d overdue | Pending | Dec 28, 2023 |
| 18541680 | METHODS AND COMPOSITIONS FOR PREDICTING AND PREVENTING RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA | DAVIS, BRIAN J | 1614 | §102§112 | Final Rejection | — | Pending | Dec 15, 2023 |
| 18528382 | COMPOSITIONS AND METHODS FOR AUGMENTING ANTIBODY MEDIATED RECEPTOR SIGNALING | DAHLE, CHUN WU | 1641 | §102§103 | Non-Final OA | — | Pending | Dec 04, 2023 |
| 18561413 | MULTI-SPECIFIC ANTIBODY CONSTRUCTS AGAINST THE MUC1-C/EXTRACELLULAR DOMAIN (MUC1-C/ED) | CHASE, CAROL ANN | 1646 | §102§103§112DP | Non-Final OA | — | Pending | Nov 16, 2023 |
| 18289780 | COMPOSITIONS AND METHODS FOR TREATING CANCER | BELYAVSKYI, MICHAIL A | 1644 | §103Other | Final Rejection | — | Pending | Nov 07, 2023 |
| 18557225 | CLASS IIA HISTONE DEACETYLASE (HDAC) DEGRADER LIGANDS AND METHODS OF USE THEREOF | DEKARSKE, MADELINE MCGUIRE | 1622 | Other | Final Rejection | — | Pending | Oct 25, 2023 |
| 18553988 | TRANSCRIPTIONAL ENHANCED ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | COPPINS, JANET L | 1628 | §112 | Final Rejection | 35d | Pending | Oct 04, 2023 |
| 18285413 | BIOORTHOGONAL REACTION SUITABLE FOR CLICK/UNCLICK APPLICATIONS | DONOHUE, SEAN R | 1618 | §102§103 | Final Rejection | — | Pending | Oct 03, 2023 |
| 18283264 | ENAMINE N-OXIDES: SYNTHESIS AND APPLICATION TO HYPOXIA-RESPONSIVE PRODRUGS AND IMAGING AGENTS | BURKETT, DANIEL JOHN | 1624 | §112 | Non-Final OA | — | Pending | Sep 21, 2023 |
| 18280877 | EP300 DEGRADER AND USES THEREOF IN NEUROBLASTOMA | HUI, SAN MING R | 1627 | §112Other | Final Rejection | — | Pending | Sep 07, 2023 |
| 18274823 | METHODS OF TREATING CANCERS USING STING AGONISTS | CRAIGO, BAHAR ALAWI | 1699 | §103 | Final Rejection | 12d | Pending | Jul 28, 2023 |
| 18224865 | GENERATION OF ANTI-TUMOR T CELLS | NATARAJAN, MEERA | 1643 | §102 | Non-Final OA | — | Pending | Jul 21, 2023 |
| 18141278 | COMPOSITION AND METHODS OF GENOME EDITING OF B-CELLS | VIVLEMORE, TRACY ANN | 1638 | §102§112DP | Final Rejection | — | Pending | Apr 28, 2023 |
| 18031257 | GERMLINE BIOMARKERS OF CLINICAL RESPONSE AND BENEFIT TO IMMUNE CHECKPOINT INHIBITOR THERAPY | HINES, JANA A | 1645 | §101 | Non-Final OA | 15d overdue | Pending | Apr 11, 2023 |
| 18030433 | CHIMERIC CONJUGATES FOR DEGRADATION OF VIRAL AND HOST PROTEINS AND METHODS OF USE | REYNOLDS, FRED H | 1658 | §103§112 | Non-Final OA | 20d | Pending | Apr 05, 2023 |
| 18026746 | METHODS OF TREATING AN INDIVIDUAL THAT HAS FAILED AN ANTI-PD-1/ANTI-PD-L1 THERAPY | BENAVIDES, JENNIFER ANN | 1675 | §102§103§112Other | Non-Final OA | 18d overdue | Pending | Mar 16, 2023 |
| 18018207 | ARYL SUBSTITUTED PYRROLO-PYRIDINONES AND THERAPEUTIC USES THEREOF | MARTIN, KEVIN STEPHEN | 1624 | §112 | Final Rejection | 31d overdue | Pending | Jan 26, 2023 |
| 18018148 | SUBSTITUTED PYRROLO-PYRIDINONE DERIVATIVES AND THERAPEUTIC USES THEREOF | TOWNSLEY, SARA ELIZABETH | 1629 | §103Other | Final Rejection | 29d | Pending | Jan 26, 2023 |
| 18061369 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA | SHELTON, SYNPHANE LA'SHAWN | 1652 | §112 | Final Rejection | 26d | Pending | Dec 02, 2022 |
| 18008108 | ANTAGONISTIC BIPARATOPIC ANTIBODIES THAT SPECIFICALLY BIND FIBROBLAST GROWTH FACTOR RECEPTOR 2 AND METHODS OF USING SAME | GANGLE, BRIAN J | 1645 | §112 | Final Rejection | — | Pending | Dec 02, 2022 |
| 17934553 | 3-(ANILINO)-2-[3-(3-ALKOXY-PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER | BRAUN, MADELINE E | 1624 | §112 | Non-Final OA | 79d overdue | Pending | Sep 22, 2022 |
| 17801709 | POTENT AND SELECTIVE DEGRADERS OF ALK | HEITMEIER, KENDALL NICOLE | 1621 | §102§103§112 | Final Rejection | 182d overdue | Pending | Aug 23, 2022 |
| 17785561 | STRUCTURALLY-STABILIZED ONCOLYTIC PEPTIDES AND USES THEREOF | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §103Other | Final Rejection | 66d overdue | Pending | Jun 15, 2022 |
| 17832911 | Immunomodulation by IAP Inhibitors | HOWELL, THEODORE R | 1628 | Other | Non-Final OA | 22d | Pending | Jun 06, 2022 |
| 17732926 | BLOOD-BASED BIOMARKERS AND USE THEREOF FOR TREATING CANCER | MCCOLLUM, ANDREA K | 1674 | §102§112 | Final Rejection | 309d overdue | Pending | Apr 29, 2022 |
| 17725407 | METHODS AND COMPOSITIONS FOR THE POSITIVE SELECTION OF PROTEIN DESTABILIZERS | LEE, JAE W | 1656 | §103§112 | Non-Final OA | 8d | Pending | Apr 20, 2022 |
| 17767035 | COMPOSITIONS AND METHODS FOR TREATING CYTOTOXIC T CELL RESISTANT TUMORS | LU, CHENG | 1642 | §103§112Other | Final Rejection | 16d | Pending | Apr 06, 2022 |
| 17766189 | IMMUNOMODULATORY IMIDE DRUGS AS ZETA-CHAIN-ASSOCIATED PROTEIN KINASE 70 (ZAP70) AGONISTS AND USES THEREOF | WHITE, DAWANNA SHAR-DAY | 1627 | §102Other | Non-Final OA | 5d | Pending | Apr 01, 2022 |
| 17687246 | COMPOSITION AND METHODS OF GENOME EDITING OF B-CELLS | VIVLEMORE, TRACY ANN | 1638 | §112Other | Final Rejection | 70d | Pending | Mar 04, 2022 |
| 17634465 | IMMUNE SIGNATURES PREDICTIVE OF RESPONSE TO PD-1 BLOCKADE IN RICHTER'S TRANSFORMATION | VANN-OJUEKAIYE, KENDRA RAYCHELL | 1682 | §103§112 | Non-Final OA | — | Pending | Feb 10, 2022 |
| 17628794 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 AND USES THEREOF | CORNET, JEAN P | 1628 | §103§112 | Final Rejection | 28d | Pending | Jan 20, 2022 |
| 17621057 | HCK DEGRADERS AND USES THEREOF | LADD, CAROLYN LOUISE | 1622 | DP | Final Rejection | — | Pending | Dec 20, 2021 |
| 17595671 | COMBINATION THERAPY | SKOKO III, JOHN JOSEPH | 1643 | §103DP | Final Rejection | 72d overdue | Pending | Nov 22, 2021 |
| 17402018 | GENETIC ABNORMALITIES IN PLASMA CELL DYSCRASIAS | GOLDBERG, JEANINE ANNE | 1682 | §103§112 | Non-Final OA | 131d overdue | Pending | Aug 13, 2021 |
| 17414480 | METHODS FOR IDENTIFYING NEOANTIGENS | FONSECA LOPEZ, FRANCINI ALVARENGA | 1685 | §101§102§103 | Non-Final OA | 58d overdue | Pending | Jun 16, 2021 |
| 17241935 | DRUG DELIVERY COMPOSITIONS AND USES THEREOF | MERTZ, PREMA MARIA | 1674 | §102§103§112 | Non-Final OA | 29d overdue | Pending | Apr 27, 2021 |
| 17213417 | COMPOSITIONS AND METHODS FOR CELL TRANSPLANTATION | MOSS, NATALIE M | 1653 | §103§112 | Final Rejection | — | Pending | Mar 26, 2021 |
| 17265139 | HISTONE DEMETHYLASE 5 INHIBITORS AND USES THEREOF | PECKHAM, RICHARD GRANT | 1627 | §102§112 | Final Rejection | 42d overdue | Pending | Feb 01, 2021 |
| 16825269 | BORONIC ESTER PRODRUGS AND USES THEREOF | BAKSHI, PANCHAM | 1623 | §112 | Non-Final OA | — | Pending | Mar 20, 2020 |
| 16739866 | FUNCTIONAL ANALYSIS OF CANCER CELLS | LU, FRANK WEI MIN | 1683 | §103 | Non-Final OA | 105d overdue | Pending | Jan 10, 2020 |
| 15768853 | POLYMERASE Q AS A TARGET IN HR-DEFICIENT CANCERS | DENT, ALANA HARRIS | 1643 | §103 | Non-Final OA | — | Pending | Apr 17, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDana-Farber Cancer Institute Inc. has 50 pending office actions as of October 2026, spread across 30 art units and 48 examiners.
Meredith Abbott Vassell has the most, with 2 of Dana-Farber Cancer Institute Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
